European Gram Negative AntiBacterial Engine
ENABLE
The ENABLE project was launched
in February 2014 (ends in January 2021) within IMI's 'New Drugs for
Bad Bugs' (ND4BB) programme. Please note that due to
ENABLE ending very soon we are not accepting Expressions of
Interest (EoIs) anymore.
The ENABLE consortium is working to advance the development of promising new antibiotic compounds targeting Gram-negative bacteria such as Escherichia coli. The goal of the project is to develop attractive antimicrobial candidates for extensive preclinical studies and First-in-Human clinical trials, bringing new antibiotics to treat Gram-negative infections one step closer to patients.
ENABLE manages a drug discovery and development engine for testing and optimising compounds in all preclinical phases of antibiotic development. ENABLE is an initiative targeted at SMEs and research institutes.
Goals of ENABLE:
• three antibacterial
Leads
• two antibacterial
Development Candidates
• at least one compound into
preclinical and Phase 1 clinical studies
What can ENABLE do for
you?
ENABLE is not only a source of funding to advance your most promising compounds, but it is also:
an alliance and collaboration to advance one common goal: fighting AMR
In ENABLE you will benefit from
a well-developed drug discovery and development platform that helps
you advance your programme in a very efficient manner. We have
experts and staff in many fields including microbiology, chemistry,
ADME, in vivo studies and safety that will support you to bring
your compound forward.
your support
for everyday challenges
The ENABLE team and our experts are easy to approach and eager to
support. We can assist you in developing a detailed project plan
that is in line with Big Pharma.
supporting “raw
diamonds”
If your programme is not yet
meeting thresholds with regards to compound maturity or generated
data package, ENABLE offers a Material Transfer Agreement (MTA)
Route – a kind of pre-ENABLE funding. If accepted, this will also
be 100% funded by ENABLE.
non-dilutive
Your compound is your compound
and will stay your compound. Programme owners retain full ownership
of their asset and all value added through the work of ENABLE.
A value sharing agreement has been created within the
consortium, where a small percentage of future income
generated from the resulting anti-bacterial by the programme owner
will be shared between partners.
and of course
confidential
ENABLE has a very restrictive
communication policy and only communicates what you agreed upon or
released yourself.
What ENABLE needs from you for a fruitful cooperation:
LATEST NEWS
ENABLE Annual Meeting
February 12, 2018
The 5th Annual Meeting of the
ENABLE consortium will take place in Riga 10-12 September
2018
ENABLE at
Berlin Conference
February 28th, 2018
ENABLE was official partner of the 11th Berlin Conference on Novel Antimicrobials and AMR Diagnostics. The conference took place on the 2 March 2018 and ENABLE partners contributed to different sessions and the Marketplace.
ENABLE
released its fifth external
newsletter
March, 2018
To read the fifth issue, click here
You can also suscribe to our Newsletter by sending an email to Dr Nathalia Murillo
info@nd4bb-enable.eu
UPCOMING EVENTS
BIO Europe Spring
BIO International Convention
Tel:
Email:
0032 2 588 70 71
info@nd4bb-enable.eu
The research leading to these results has received support from the Innovative Medicine Initiative Joint Undertaking under grant agreement no 115583, resources of which are composed of financial contributions from the European Union`s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies` in kind contribution.
